What is Sensus Healthcare's latest dividend and current dividend yield?

What does Sensus Healthcare do and what are its main business segments?

What factors drove the changes in Sensus Healthcare's revenue and profit?

What is the market's earnings forecast for Sensus Healthcare next quarter?

What were the key takeaways from Sensus Healthcare's earnings call?

What is Sensus Healthcare's gross profit margin?

Did Sensus Healthcare beat or miss consensus estimates last quarter?

What were the key takeaways from Sensus Healthcare’s earnings call?

- **CPT Code Breakthrough**: Exclusive reimbursement codes enable noninvasive skin cancer treatment, diversifying revenue and reducing customer concentration risk.
- **Q1 2026 Growth**: Shipments expected to exceed Q4 2025, driven by direct sales and international expansion (China, Brazil).
- **Financial Strength**: $22M cash, no debt; targeting 2026 full-year profitability with disciplined cost control.
- **FDA Program Success**: 2025 utilization up 8x, with customers converting to outright purchases post-reimbursement clarity.
- **Risk Note**: Largest customer exclusion from 2026 projections; TDI regulatory timeline uncertain.

**【CEO Opening Remarks】**
- **New CPT Codes**: Exclusive reimbursement codes for SRT and IG-SRT technology, addressing non-melanoma skin cancer, providing clear physician reimbursement and reducing reliance on a single large customer.
- **Q4 2025 Performance**: Shipped 14 units (none to largest customer), with international sales to China and other markets. Ended with $22M cash, 0 debt, and plans to expand sales force.
- **2026 Outlook**: Expect Q1 shipments > Q4 2025, targeting full-year profitability. International growth and diversified customer base are key drivers.

**【Michael Sardano - Commercial Strategy】**
- **Fair Deal Agreement (FDA) Program**: 2025 utilization up 8x in treatments and 250% in patients, with 18 active sites. Customers increasingly opting for outright purchases post-reimbursement clarity.
- **International Expansion**: Strong demand in China, Taiwan, and Brazil (pending regulatory approval). MDSAP certification opens doors to Japan and South Korea.
- **Sales Team Scaling**: Adding 3-5 reps in Q1 2026 to accelerate lead conversion, with targeted trade show strategy for high-impact events.

**【Javier Rampolla - Financial Highlights】**
- **Q4 2025 Results**: Revenue $4.9M (vs. $3.1M prior year), net loss $3.2M due to lower unit sales and FDA program costs. Gross margin 38.8%, down from 54.2% prior year.
- **Full Year 2025**: Revenue $27.5M (vs. $41.8M), net loss $7.7M. Adjusted EBITDA negative $9.6M. Ended with $22M cash, no debt.
- **2026 Guidance**: Q1 revenue > Q4 2025, targeting full-year profitability. Inventory build for anticipated demand.

**【Q&A Highlights】**
- **Largest Customer Outlook**: 2026 projections exclude contributions from largest customer, but open to collaboration if circumstances allow.
- **International Momentum**: China, Taiwan, and Brazil driving growth. Brazil regulatory clearance expected in 2026.
- **Product Mix & Service Revenue**: Smaller practices favor outright purchases/leases; service revenue remains ~10% of total.
- **TDI Regulatory Update**: Ongoing FDA engagement, but timeline uncertain; pursuing alternative pathways.

Sensus Healthcare, Inc. (SRTS) Q4 2025 Earnings Call Transcript

- **CPT Code Breakthrough**: CMS approves dedicated SRT codes with 300%+ reimbursement increase, validating office-based SRT economics.
- **Fair Deal Growth**: Treatment volumes up 20% Q/Q and 157% since launch, driven by patient demand and physician adoption.
- **International Expansion**: 3 Q3 systems shipped to China; MDSAP certification opens 5 new markets, targeting 20%+ international revenue.
- **Cash Position**: $24.5M in cash with 100+ systems in inventory to capitalize on pent-up demand.
- **Sentinel 2.0**: Software upgrade to bring SRT-100 functionality parity with Vision, supporting network adoption.

**【CEO Summary Section】**
- Announced CMS approval of dedicated CPT codes for superficial radiotherapy (SRT), with a 300%+ increase in reimbursement per fraction compared to prior codes.
- Shipped 16 SRT systems in Q3, including 3 to China, bringing total global systems sold to over 900.
- Fair Deal program treatment volumes grew 20% Q/Q and 52% Y/Y, with 157% growth since program launch.
- Ended Q3 with $24.5M in cash and 100+ systems in inventory to support demand.

**【President (Michael Sardano) Business Update】**
- New CPT codes level the reimbursement playing field between hospital and office-based settings, enhancing ROI for dermatologists.
- Sentinel 2.0 software development underway to expand analytics and support recurring revenue models.
- International expansion progress: MDSAP certification enables entry into 5 key markets, with first Japan trade show in November.
- TDI system awaiting FDA feedback, with focus on commercial readiness.

**【CFO Financial Commentary】**
- Q3 2025 revenue $6.9M (-22% YoY) due to lower system sales volume, offset by Fair Deal program revenue.
- Gross margin 39.1% (vs. 59.1% YoY) due to higher servicing costs and program expenses.
- Operating expenses $5.3M (+43% YoY) driven by R&D (lobbying, product dev), G&A, and sales headcount growth.
- Net loss $0.9M (-92% YoY) with negative Adjusted EBITDA of $2.4M.
- Year-to-date cash balance up 11% to $24.5M, supported by working capital management.

**【Q&A Highlights】**
- **Reimbursement Impact**: SRT-100 base units now have higher reimbursement than IG-SRT, potentially shifting demand.
- **Utilization Momentum**: 20% Q/Q growth in Fair Deal treatments, with 11 pending sites expected to activate in Q4.
- **International Outlook**: Target 20% of revenue from international markets within 24 months, with China and Japan as key growth drivers.
- **LCD Resolution**: CMS finalized ultrasound guidance code, resolving prior uncertainty and enabling full SRT adoption.
- **Sentinel 2.0**: SRT-100 units will gain Vision-level capabilities, enhancing value for dermatology networks.


Sensus Healthcare, Inc. (SRTS) Q3 2025 Earnings Call Transcript

- **Domestic Reimbursement Risk**: Q2 sales stalled due to Medicare LCD uncertainty; resolution expected by Q4 2025.
- **Reimbursement Boost Potential**: Proposed 300% increase in SRT delivery codes could triple U.S. demand.
- **International Growth**: 4 China sales, MDSAP certification opens 4 new markets, FDA volume +27% YoY.
- **Financial Health**: $22.2M cash cushion despite $1.0M net loss; ROS partnership to accelerate oncology penetration.

**【CEO Summary Section】**
- Q2 2025 domestic sales momentum stalled due to a proposed LCD limiting reimbursement for ultrasound usage with SRT-100 Vision systems. The company is actively lobbying against this LCD, which could impact Medicare reimbursement for ultrasound frequency.
- A proposed 300% increase in SRT delivery code reimbursement under the Medicare physician fee schedule could significantly boost U.S. demand, aligning outpatient and hospital reimbursement rates.
- International growth: 4 systems sold to China, and MDSAP certification grants access to Brazil, Japan, Canada, and Australia. FDA treatment volume increased 27% YoY.
- New partnership with Radiation Oncology Systems (ROS) to expand into hospital-based oncology markets.

**【CFO Financial Commentary】**
- Q2 2025 revenue $7.3M (-20.7% YoY) due to fewer capital sales, offset by recurring Fair Deal Agreement revenue growth.
- Gross margin 39.7% (-19.0pp YoY) from lower sales and higher service costs.
- Operating expenses increased: G&A ($2.0M vs $1.6M), Sales/Marketing ($1.4M vs $1.0M), R&D ($1.5M vs $0.9M).
- Net loss $1.0M (-106% YoY); cash balance $22.2M.

**【Q&A Key Highlights】**
- **LCD Resolution Timeline**: CMS expected to clarify LCD by Q4 2025; company optimistic about maintaining status quo.
- **Sales Impact**: Large U.S. customer paused purchases; resumption contingent on LCD clarity. China sales remain variable but growing.
- **International Expansion**: Upcoming meetings in Japan/Taiwan to leverage MDSAP for Asian market entry.
- **ROS Partnership**: Expected to drive hospital-based SRT adoption in U.S. by Q4 2025.
- **Reimbursement Outlook**: Proposed fee schedule changes could triple SRT delivery code reimbursement, accelerating unit installations post-resolution.

Sensus Healthcare, Inc. (SRTS) Q2 2025 Earnings Call Transcript

- **Revenue Recovery Expected**: Q1 2025 revenue down 22% YoY, but management forecasts sequential growth with Q2 > Q1 and H2 > H1, driven by FDA contributions and direct sales.
- **FDA Momentum**: 65% QoQ increase in FDA patient treatments; targeting 3-5 multi-site FDA customers in 2025 for recurring revenue.
- **Financial Discipline**: Despite Q1 net loss of $2.6 million, strong cash position ($19.1M) and plans to reduce operating expenses by ~30% in future quarters.
- **Innovation Pipeline**: TDI 510(k) review on track for end-2025; FDA program expansion into international markets (Europe, Australia).
- **Profitability Outlook**: Expect profitability in each of the next three quarters and full-year profitability, supported by scaling FDA revenue and cost control.

**【CEO Summary Section】**
- Q1 2025 revenue was $8.3 million, down 22% YoY due to lower sales to the largest customer. Total SRT systems shipped: 21 (15 to largest customer, 1 international), bringing the installed base to 880.
- 11 Fair Deal Agreements (FDA) were initiated, with 6 going live in Q1. Patient treatments from FDA installations increased 65% QoQ, signaling strong adoption.
- Management expects Q2 revenue > Q1 and H2 > H1, with profitability in each of the next three quarters and full-year profitability.
- Key initiatives: expanded marketing (e.g., AED event with Katie Ledecky), FDA program expansion (targeting 3-5 multi-site FDA customers in 2025), and international growth (ESTRO, Australian Dermatology shows).

**【CFO Financial Commentary】**
- Q1 GAAP net loss: $2.6 million (-13% YoY). Gross margin: 52% (stable vs. Q1 2024). Operating expenses: 
  - G&A: $2.2 million (+38% YoY) due to professional fees and compensation.
  - Sales & marketing: $2.2 million (+70% YoY) driven by event participation.
  - R&D: $2.6 million (+190% YoY) for TDI development.
- Expect lower expenses in future quarters: G&A ~$1.8 million/Q, S&M ~$1.3 million/Q, R&D ~$1.5 million/Q.
- Cash: $19.1 million (no debt), inventory: $9.9 million to meet demand.

**【Q&A Key Highlights】**
- **FDA Contribution**: Management expects significant revenue from FDA in H2 2025, with 4-5 months lag between agreement signing and revenue generation. 65% QoQ growth in FDA patient treatments reflects accelerating utilization.
- **TDI Progress**: 510(k) resubmitted in March; no FDA follow-up questions yet. Anticipate determination by end-2025. TDI revenue model and go-to-market strategy being finalized.
- **Tariff Impact**: No material impact on business to date.
- **Sales Strategy**: Targeting high-volume practices (e.g., rural dermatology clinics) for FDA installations, leveraging analytics to identify high-potential sites.
- **Expense Management**: One-time Q1 costs (e.g., legal expenses) are unlikely to recur; expect improved margins as FDA revenue scales.


Sensus Healthcare, Inc. (SRTS) Q1 2025 Earnings Call Transcript

- **Record growth**: 2024 revenue up 71% to $41.8M, driven by 115 SRT-100 units shipped globally.
- **FDA program momentum**: No upfront capital agreements signed with large dermatology groups, with H2 2025 revenue contribution expected.
- **Largest customer expansion**: 50-unit PO from key client, 25 delivered Q4 with 25 scheduled for 2025.
- **New market diversification**: Veterinary SRT pilot launched, targeting non-invasive animal tumor treatment.
- **Profitability maintained**: 5th consecutive quarter of net income, with $22.1M cash balance for growth initiatives.

**【CEO Summary Section】**
- Q4 2024 revenue reached $13.1 million, up 4% YoY, with full year revenue of $41.8 million (71% YoY growth), driven by 115 SRT-100 units shipped globally.
- Achieved 5th consecutive quarter of profitability with Q4 net income of $1.4 million and $6.6 million for the year.
- Key initiatives: Fair Deal Agreement (FDA) program expansion, veterinary market pilot, and TBI-510K regulatory resubmission planned for H1 2025.
- Largest customer signed 50-unit PO, with 25 delivered in Q4 and 25 scheduled for 2025.

**【CFO Financial Commentary】**
- Q4 gross profit: $7.1 million (54.4% margin), down 800bps YoY due to one-time discounts and higher service costs.
- Operating expenses: G&A up 167% YoY to $2.4 million (higher compensation), R&D up 129% to $1.6 million.
- Full year cash balance: $22.1 million (no debt), supporting R&D and sales initiatives.
- Q1 2025 sales expected lower due to medical conference seasonality, but full year growth anticipated.

**【FDA Program & Strategic Growth】**
- FDA agreements signed with large dermatology groups, offering no upfront capital and recurring revenue streams.
- Focus on high-volume clinics: 50% of 2024 units went to corporate accounts, with 10% international shipments.
- Veterinary market pilot: 1 unit sold to South Florida clinic, targeting non-invasive animal tumor treatment.

**【Q&A Key Takeaways】**
- FDA agreement revenue contribution expected in H2 2025, with patient volume tracking as key metric.
- No new competitors in SRT space; primary alternative is Mohs surgery.
- Largest customer (25 units Q4) represents ~60% of quarterly shipments, with continued 2025 orders.
- TBI-510K resubmission expected Q2 2025, targeting enhanced SRT capabilities for larger tumors.

Actual												-0.22	-0.16	-0.1	0.06	-0.07	-0.02	0.01	0.32	0.97	0.21	0.11	0.17	-0.12	-0.02	-0.09	0.26	0.14	0.1	0.07	0.09	-0.16	-0.06	-0.06	-0.19
Forecast												-0.085	-0.1767	-0.135	-0.1117	-0.0983	-0.055	-0.0167	0.164	0.0433	0.132	0.126	0.23	0.125	-0.076	-0.018	0.1425	-0.0433	0.0233	-0.01	0.124	0.034	0.026	-0.095	-0.07
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-158.82%	+9.45%	+25.93%	+153.72%	+28.79%	+63.64%	+159.88%	+95.12%	+2140.18%	+59.09%	-12.70%	-26.09%	-196.00%	+73.68%	-400.00%	+82.46%	+423.33%	+329.18%	+800.00%	-27.42%	-570.59%	-330.77%	+36.84%	-171.43%

SRTS

SRTS fundamentals

SRTS Q4 2025 Earnings

Earnings Call

You can ask Aime

SRTS

SRTS fundamentals

SRTS Q4 2025 Earnings

Earnings Call

SRTS Earnings Call Summary for Q4/20254:30 PM on Feb 12, 2026

SRTS Earnings Call Summary for Q3/20254:30 PM on Nov 6, 2025

SRTS Earnings Call Summary for Q2/20254:30 PM on Aug 7, 2025

SRTS Earnings Call Summary for Q1/20254:30 PM on May 15, 2025

SRTS Earnings Call Summary for Q4/20244:30 PM on Feb 5, 2025

You can ask Aime